abrdn Life Sciences Investors (HQL)
Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.
abrdn Life Sciences Investors
- 0.6%
- 182.2K
- 1.71
Float 30.41M · Polygon free float · Mar 16, 2026
The cost to borrow HQL shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 55.0%
- 74
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 182.2K sh |
| Oct 15, 2026 | 192.7K sh |
| Sep 30, 2026 | 112.8K sh |
| Sep 15, 2026 | 67.4K sh |
| Aug 31, 2026 | 100.2K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Sep 28, 2026 | 74 sh |
| Sep 25, 2026 | 81 sh |
| Sep 24, 2026 | 96 sh |
| Sep 15, 2026 | 374 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 55.0% |
| Nov 16, 2026 | 37.1% |
| Nov 13, 2026 | 76.6% |
| Nov 12, 2026 | 67.5% |
| Nov 11, 2026 | 45.2% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for HQL: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 182,216 HQL shares were sold short (0.60% of a 30.41M-share float, 1.71 days to cover).